OBJECTIVES: Neuropsychiatric symptoms are common in patients with Alzheimer disease (AD). Treatment for both AD and psychiatric disturbances may affect the clinical observed pattern and comorbidity. The authors aimed to identify whether particular neuropsychiatric syndromes occur in untreated patients with AD, establish the severity of syndromes, and investigate the relationship between specific neuropsychiatric syndromes and AD disease severity. DESIGN: Cross-sectional, multicenter, clinical study. PARTICIPANTS: A total of 1,015 newly diagnosed, untreated outpatients with AD from five Italian memory clinics were consecutively enrolled in the study from January 2003 to December 2005. MEASUREMENTS: All patients underwent thorough examination by clinical neurologists/geriatricians, including neuropsychiatric symptom evaluation with the Neuropsychiatric Inventory. RESULTS: Factor analysis revealed five distinct neuropsychiatric syndromes: the apathetic syndrome (as unique syndrome) was the most frequent, followed by affective syndrome (anxiety and depression), psychomotor (agitation, irritability, and aberrant motor behavior), psychotic (delusions and hallucinations), and manic (disinhibition and euphoria) syndromes. More than three quarters of patients with AD presented with one or more of the syndromes (N = 790, 77.8%), and more than half exhibited clinically significant severity of symptoms (N = 603, 59.4%). With the exception of the affective one, all syndromes showed an increased occurrence with increasing severity of dementia. CONCLUSIONS: The authors' study supports the use of a syndrome approach for neuropsychiatric evaluation in patients with AD. Individual neuropsychiatric symptoms can be reclassified into five distinct psychiatric syndromes. Clinicians should incorporate a thorough psychiatric and neurologic examination of patients with AD and consider therapeutic strategies that focus on psychiatric syndromes, rather than specific individual symptoms.
OBJECTIVES:Neuropsychiatric symptoms are common in patients with Alzheimer disease (AD). Treatment for both AD and psychiatric disturbances may affect the clinical observed pattern and comorbidity. The authors aimed to identify whether particular neuropsychiatric syndromes occur in untreated patients with AD, establish the severity of syndromes, and investigate the relationship between specific neuropsychiatric syndromes and AD disease severity. DESIGN: Cross-sectional, multicenter, clinical study. PARTICIPANTS: A total of 1,015 newly diagnosed, untreated outpatients with AD from five Italian memory clinics were consecutively enrolled in the study from January 2003 to December 2005. MEASUREMENTS: All patients underwent thorough examination by clinical neurologists/geriatricians, including neuropsychiatric symptom evaluation with the Neuropsychiatric Inventory. RESULTS: Factor analysis revealed five distinct neuropsychiatric syndromes: the apathetic syndrome (as unique syndrome) was the most frequent, followed by affective syndrome (anxiety and depression), psychomotor (agitation, irritability, and aberrant motor behavior), psychotic (delusions and hallucinations), and manic (disinhibition and euphoria) syndromes. More than three quarters of patients with AD presented with one or more of the syndromes (N = 790, 77.8%), and more than half exhibited clinically significant severity of symptoms (N = 603, 59.4%). With the exception of the affective one, all syndromes showed an increased occurrence with increasing severity of dementia. CONCLUSIONS: The authors' study supports the use of a syndrome approach for neuropsychiatric evaluation in patients with AD. Individual neuropsychiatric symptoms can be reclassified into five distinct psychiatric syndromes. Clinicians should incorporate a thorough psychiatric and neurologic examination of patients with AD and consider therapeutic strategies that focus on psychiatric syndromes, rather than specific individual symptoms.
Authors: David L Sultzer; Lorraine P Leskin; Rebecca J Melrose; Dylan G Harwood; Theresa A Narvaez; Timothy K Ando; Mark A Mandelkern Journal: Am J Geriatr Psychiatry Date: 2013-09-08 Impact factor: 4.105
Authors: John D Outen; M Haroon Burhanullah; Ryan Vandrey; Halima Amjad; David G Harper; Regan E Patrick; Rose L May; Marc E Agronin; Brent P Forester; Paul B Rosenberg Journal: Am J Geriatr Psychiatry Date: 2021-01-27 Impact factor: 4.105
Authors: Ye Tao; Matthew E Peters; Lea T Drye; Davangere P Devanand; Jacobo E Mintzer; Bruce G Pollock; Anton P Porsteinsson; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos; Cynthia A Munro Journal: Am J Alzheimers Dis Other Demen Date: 2018-07-03 Impact factor: 2.035
Authors: Iris E C Sommer; Christina W Slotema; Zafiris J Daskalakis; Eske M Derks; Jan Dirk Blom; Mark van der Gaag Journal: Schizophr Bull Date: 2012-02-24 Impact factor: 9.306
Authors: Zahinoor Ismail; Chetachi A Emeremni; Patricia R Houck; Sati Mazumdar; Jules Rosen; Tarek K Rajji; Bruce G Pollock; Benoit H Mulsant Journal: Am J Geriatr Psychiatry Date: 2013-01-02 Impact factor: 4.105
Authors: Natalia Sonsin-Diaz; Rebecca F Gottesman; Elizabeth Fracica; Jeremy Walston; B Gwen Windham; David S Knopman; Keenan A Walker Journal: Am J Geriatr Psychiatry Date: 2019-05-21 Impact factor: 4.105
Authors: Virginia E Sturm; Jennifer S Yokoyama; William W Seeley; Joel H Kramer; Bruce L Miller; Katherine P Rankin Journal: Proc Natl Acad Sci U S A Date: 2013-05-28 Impact factor: 11.205